Skip to main content

Combimatrix Reports a Jump in Q3 Revenues; R&D Flat

NEW YORK, Oct. 21 (GenomeWeb News) - CombiMatrix reported third-quarter 2004 revenues of $753,000, up from $181,000 in the third quarter of 2003, the company's parent, Acacia Research, reported today.


Revenues for the quarter included $685,000 in "government contract revenues" and $68,000 in "microarray product sales and other contract service revenues," said the company.


Research and development expenses were flat at $1.7 million for the period year over year. These expenses included increased government contract costs incurred in connection with the company's commitments under its Department of Defense biowarfare detection contract, and other interenal R&D efforts, the company said.


Net loss narrowed by 22.8 percent, to $3.5 million during the third quarter of 2004 from $4.5 million during the comparable period in 2003, the company added.


CombiMatrix had around $26.7 million in cash, equivalents, and short-term investments as of Sept. 30.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.